Trial of anakinra for FMF attacks in patients who refuse daily shots
Treatments studied
Part of Genetic & congenital clinical trials.
This trial tests if taking anakinra (a targeted medicine) only when you have a painful FMF attack can help, instead of taking it every day. It is for people with Familial Mediterranean Fever (FMF) whose attacks continue despite taking colchicine, and who do not want daily injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 6 years or older
- You have been diagnosed with FMF by specific criteria and have two proven MEFV gene changes
- You still get FMF attacks (like arthritis, chest pain, belly pain, muscle pain, or skin redness lasting 1–4 days) at least once a month even on the highest dose of colchicine
- You have decided not to take daily anakinra shots
- You do not have active tuberculosis or frequent severe infections
- You are not pregnant and are willing to use effective birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether RPH-104 can help prevent recurrent fever attacks in adults with Familial Mediterranean Fever (FMF) who cannot tolerate colchicine or whose disease does not respond to it. Participants may receive the medicine at the clinic or learn to give it as a self-injection, depending on what fits your situation.
This trial tests whether a medicine called anakinra can help children with acute myocarditis (heart inflammation) in the ICU. It aims to see if the drug reduces heart damage and improves recovery.
This study looks at the gut bacteria (microbiome) in people with autoinflammatory diseases. It may help researchers understand how bacteria in the gut affect inflammation and find better ways to treat these conditions.
This study looks at how well and safely different real-world treatments work for people with Familial Mediterranean Fever (FMF). It aims to find which medicines help best for this inherited inflammatory disorder.
This Phase 2 study tests whether a medicine called anakinra, given as under-the-skin injections, is safe and may improve lung outcomes in adults with cystic fibrosis. You may be able to join if you meet specific breathing and lab criteria and can follow the study schedule.
This study measures levels of certain proteins (caspase-1, IL-1beta, and IL-18) in tissue samples from people with Familial Mediterranean Fever (FMF). It aims to understand how these proteins relate to the disease and may help guide future treatments.
Hear when a new FMF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.